ENGN.US enGene Therapeutics Inc.

Healthcare Biotechnology USA Stocks
2.41 USD
Close of Nov 14, 2026
1.40 12.25
Market cap
USD 162M
P/E
-
P/B
0.67x
ROE
19.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.

Is ENGN.US undervalued?

Graham number

The Graham number of enGene Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

enGene Therapeutics Inc. fundamental analysis

No fundamental analysis for enGene Therapeutics Inc. yet.

enGene Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About enGene Therapeutics Inc.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to en…

Full company profile